Healthcare Industry News:  Meniscus Implant 

Devices Orthopaedic

 News Release - May 25, 2007

ReGen Biologics to Launch Lateral CMI(TM) at 6th Biennial ISAKOS Congress

FRANKLIN LAKES, NJ--(HSMN NewsFeed)--The ISAKOS congress in Florence, Italy provides the setting for several exciting events sponsored by the European subsidiary of ReGen Biologics (OTC: RGBI ). ISAKOS is the International Society of Arthroscopy, Knee Surgery, and Orthopaedic Sports Medicine.

During the meeting, ReGen will exhibit its flagship product, the CMI(TM) Meniscus Implant, which is CE marked and cleared for sale in Europe for both medial and lateral use. The lateral CMI has been the subject of a post-marketing study in Europe since receiving the CE mark in 2006 and will now be available for general sale.

ReGen is sponsoring a luncheon symposium as part of the ISAKOS scientific program. Three topics will be discussed at this symposium. Dr. Kenneth DeHaven of Rochester, New York will present the results of the CMI U.S. multicenter clinical trial. Dr. Dirk Holsten of Koblenz, Germany will review the lateral CMI surgical technique. And Dr. M. Marcacci and Dr. S. Zaffagnini of Bologna, Italy will discuss the preliminary clinical trial results of the lateral CMI.

"We are pleased to support the efforts of ISAKOS in presenting new and important information, and also to offer surgeons a proven treatment for lateral meniscus defects," said Marcel Kyburz, General Manager of ReGen Biologics AG. "We look forward to expanding our association with leading arthroscopic surgeons globally as we continue to develop state of the art products."

The ISAKOS Congress provides an international forum for the exchange of scientific information and networking with leaders in orthopedics and sports medicine from around the world. ISAKOS is the Society of the future providing high quality educational programs for its members and the orthopaedic and sports medicine global community. For more information on the society or the congress please visit

About ReGen Biologics, Inc.:

ReGen Biologics is an orthopedic products company that develops, manufactures and markets innovative tissue growth and repair products for U.S. and global markets. ReGen's patented collagen scaffold technology includes applications in orthopedics, general surgery, spine, cardiovascular and drug delivery. ReGen's first approved product using its collagen scaffold technology is the CMI(TM), a meniscus application, which is cleared for sale in Europe and marketed through ReGen's European subsidiary, ReGen Biologics AG. ReGen has submitted a 510(k) to the FDA in the U.S. for clearance of the CMI.

ReGen is headquartered in Franklin Lakes, NJ and manufactures its collagen scaffold products in its ISO Certified facility located in Redwood City, CA. For more information on ReGen, visit .

This press release contains forward-looking statements within the meaning of the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based on the current expectations and beliefs of the management of ReGen and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including those discussed in the Risk Factors section of ReGen's 2006 annual report on Form 10-K and additional filings with the SEC. ReGen's filings with the SEC are available to the public at the Company's website at, from commercial document-retrieval services and at the Web site maintained by the SEC at .

Source: ReGen Biologics

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.